drugset / Trial / NCT07236528
Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
Phase 2
Not yet recruiting
30 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, multicenter, single arm, open label study aimed at evaluating the efficacy and safety of the combination of Carilizumab, Apatinib Mesylate, and first-line radiotherapy for advanced mucosal melanoma.
Timeline
- Start
- 2025-11-30
- Primary completion
- 2027-12-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |